Literature DB >> 32414722

Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment.

Ahmed Hussain1, Preya J Patel1, Freya Rhodes1, Ankur Srivastava1, David Patch1, William Rosenberg2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) accounts for 10-15% of orthotopic liver transplants (OLTs) in the UK. Index presentations with cirrhotic decompensation represent missed opportunities for preventive treatment leaving OLT or palliation as the only options.We retrospectively reviewed patient records for all NAFLD patients undergoing assessment for OLT between January 2003 and December 2017.Data were available for 81 patients with NAFLD as the primary diagnosis. Fifty-two patients had decompensated cirrhosis at first presentation; 91.7% presented to secondary care compared to 52.7% referred from primary care (p=0.001). Cirrhosis was not suspected at the time of referral to hospital in 24.7% of patients subsequently assessed for OLT. Most patients undergoing assessment for OLT for NAFLD had decompensated cirrhosis at their first diagnosis of chronic liver disease. These data highlight the plight of patients with NAFLD cirrhosis in whom chronic liver disease is diagnosed late. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  Non-alcoholic fatty liver disease; cirrhosis; decompensation; prognosis; transplantation

Mesh:

Year:  2020        PMID: 32414722      PMCID: PMC7354028          DOI: 10.7861/clinmed.2019-0250

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  27 in total

1.  Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR).

Authors:  René Adam; Vincent Karam; Valérie Delvart; John O'Grady; Darius Mirza; Jurgen Klempnauer; Denis Castaing; Peter Neuhaus; Neville Jamieson; Mauro Salizzoni; Stephen Pollard; Jan Lerut; Andreas Paul; Juan Carlos Garcia-Valdecasas; Fernando San Juan Rodríguez; Andrew Burroughs
Journal:  J Hepatol       Date:  2012-05-16       Impact factor: 25.083

2.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.

Authors:  Ankur Srivastava; Ruth Gailer; Sudeep Tanwar; Paul Trembling; Julie Parkes; Alison Rodger; Deepak Suri; Douglas Thorburn; Karen Sennett; Sarah Morgan; Emmanuel A Tsochatzis; William Rosenberg
Journal:  J Hepatol       Date:  2019-04-06       Impact factor: 25.083

Review 3.  The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information.

Authors:  Ian A Rowe; Richard Parker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

4.  How to tackle rising rates of liver disease in the UK.

Authors:  Neeraj Bhala; Guruprasad Aithal; James Ferguson
Journal:  BMJ       Date:  2013-02-08

Review 5.  Non-alcoholic fatty liver disease and risk of cardiovascular disease.

Authors:  Amedeo Lonardo; Silvia Sookoian; Carlos J Pirola; Giovanni Targher
Journal:  Metabolism       Date:  2015-09-25       Impact factor: 8.694

6.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

7.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  J Hepatol       Date:  2016-04-07       Impact factor: 25.083

8.  Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance.

Authors:  Jessica Glen; Lefteris Floros; Chris Day; Rachel Pryke
Journal:  BMJ       Date:  2016-09-07

9.  Type 2 diabetes and risk of hospital admission or death for chronic liver diseases.

Authors:  Sarah H Wild; Joanne R Morling; David A McAllister; Jan Kerssens; Colin Fischbacher; Julie Parkes; Paul J Roderick; Naveed Sattar; Christopher D Byrne
Journal:  J Hepatol       Date:  2016-01-23       Impact factor: 25.083

Review 10.  Current approaches to the management of patients with cirrhotic ascites.

Authors:  Dmitry Victorovich Garbuzenko; Nikolay Olegovich Arefyev
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

View more
  5 in total

1.  COVID-19: the physician's response in the first phase.

Authors:  Anton Emmanuel
Journal:  Clin Med (Lond)       Date:  2020-05       Impact factor: 2.659

Review 2.  Identification of liver disease: why and how.

Authors:  Iain Macpherson; Kushala W M Abeysekera; Rebecca Harris; Dina Mansour; Stuart McPherson; Ian Rowe; William Rosenberg; John F Dillon; Andrew Yeoman
Journal:  Frontline Gastroenterol       Date:  2022-01-24

3.  Uncovering unsuspected advanced liver fibrosis in patients referred to alcohol nurse specialists using the ELF test.

Authors:  Freya Rhodes; Sara Cococcia; Jasmina Panovska-Griffiths; Sudeep Tanwar; Rachel H Westbrook; Alison Rodger; William M Rosenberg
Journal:  BMC Gastroenterol       Date:  2021-03-31       Impact factor: 3.067

Review 4.  Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.

Authors:  Leen J M Heyens; Dana Busschots; Ger H Koek; Geert Robaeys; Sven Francque
Journal:  Front Med (Lausanne)       Date:  2021-04-14

5.  Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients.

Authors:  Giada Sebastiani; Jovana Milic; Adriana Cervo; Sahar Saeed; Thomas Krahn; Dana Kablawi; Al Shaima Al Hinai; Bertrand Lebouché; Philip Wong; Marc Deschenes; Claudia Gioè; Antonio Cascio; Giovanni Mazzola; Giovanni Guaraldi
Journal:  J Pers Med       Date:  2022-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.